|
Allele Symbol Allele Name Allele ID |
Trp53tm2Tyj targeted mutation 2, Tyler Jacks MGI:3039263 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
20 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit very limited proliferation potential and undergo senescence sooner than control cells that become immortalized
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit increased invasion compared with control cells that is not as severe as in similarly treated cells from Trp53tm1Brn homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• pancreas contains PanINs and adenocarcinoma
|
|
• pancreas contains PanINs and adenocarcinoma
|
|
• pancreas contains PanINs and adenocarcinoma
|
|
• pancreas contains PanINs and adenocarcinoma
|
|
• most mice develop metastases which are numerous and widespread in many different sites, including the lymph nodes, diaphragm, lungs, and liver
• all mice exhibit peritoneal disseminated tumor cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit a similar overall pancreatic tumor burden as KPCT (Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0 Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+) mice
• pancreas contains PanINs and adenocarcinoma that are similar to pancreatic ductal adenocarcinoma (PDAC) in KPCT mice
• only 3 of 14 mice develop metastases, with only half of mice showing peritoneal disseminated tumor cells
• cancer cells exhibit a higher mitotic index than KPCT mice
|
|
• pancreas contains PanINs and adenocarcinoma that are similar to PDAC in KPCT mice
|
|
• mice exhibit a shorter survival than KPCT mice
|
|
• mice exhibit a similar overall pancreatic tumor burden as KPCT (Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0 Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+) mice
• pancreas contains PanINs and adenocarcinoma that are similar to pancreatic ductal adenocarcinoma (PDAC) in KPCT mice
• only 3 of 14 mice develop metastases, with only half of mice showing peritoneal disseminated tumor cells
• cancer cells exhibit a higher mitotic index than KPCT mice
|
|
• pancreas contains PanINs and adenocarcinoma that are similar to PDAC in KPCT mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 19 weeks following cre-adenovirus treatment, sinonasal adenocarninomas develop in 64% of mice
|
|
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes
|
|
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit reduced invasion compared with similarly treated cells from Trp53tm1Brn/Trp53tm2Tyj mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• however, treatment with a potent and selective oral pan class I PI3K inhibitor (GDC 0941) blocks tumor growth
|
|
• however, treatment with a potent and selective oral pan class I PI3K inhibitor (GDC 0941) blocks tumor growth
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• mice show widespread peritoneal metastases, including omentum and diaphragm
• the overall metastatic tumor burden in fallopian tube-removed mice is less extensive than that of intact mice
|
|
|
• mice develop massive high-grade serous carcinomas that always arise from the fallopian tube
• however when fallopian tubes are removed, mice develop high-grade serous carcinomas originating from the ovary, indicating that the ovary can be a source of carcinomas but is less dominant in tumorigenesis than the fallopian tube
|
|
|
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer
|
|
|
• premature death starting around 6 months of age with all mice dying by around 8 months of age
• fallopian tube-removed mice die at around 8-14 months of age after inducing ascites
|
|
|
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer
|
|
|
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| ovarian cancer | DOID:2394 |
OMIM:167000 OMIM:607893 |
J:222579 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• 70% of mice develop granulosa-cell tumors in the ovary
|
|
|
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube
|
|
|
• serous carcinoma spreads throughout the peritoneal cavity, to the omentum and across the peritoneal membrane, including the mesentery and diaphragm
|
|
|
• median survival is 11.2 months of age, with mice dying between 7.6 and 15.3 months of age
|
|
|
• 70% of mice develop granulosa-cell tumors in the ovary
|
|
|
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube
|
|
|
• 70% of mice develop granulosa-cell tumors in the ovary
|
|
|
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| ovarian cancer | DOID:2394 |
OMIM:167000 OMIM:607893 |
J:222579 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• as in mice lacking the BRF1 knock-in
|
|
• as in mice lacking the BRF1 knock-in
|
|
• tRNA levels are increased in the pancreas
|
|
• as in mice lacking the BRF1 knock-in
|
|
• tRNA levels are increased in the pancreas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
|
|
|
• distant metastases are seen in the pleura of 87.5%, in the lung of 83% and in the liver of 46% of mutants intrabursally injected with Ad-cre that develop stage IV disease
|
|
|
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma
|
|
|
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
|
|
|
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma
• oviduct lesions are characterized by a glandular/acinar histology
|
|
|
• ovaries in intrabursally Ad-cre injected mice show hemorrhagic or serous ascites
|
|
|
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| ovarian cancer | DOID:2394 |
OMIM:167000 OMIM:607893 |
J:189304 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| ovarian cancer | DOID:2394 |
OMIM:167000 OMIM:607893 |
J:189304 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
|
|
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| ovarian cancer | DOID:2394 |
OMIM:167000 OMIM:607893 |
J:189304 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes
(J:103407)
• following cre-adenovirus treatment, tumors occupy 27% of lung space
(J:103407)
• mice treated with intratracheal delivery of cre-expressing adenovirus develop lung cancer
(J:191425)
• mice infected with higher doses of cre expressing adenovirus present with clinical signs of lung cancer by 15 weeks of treatment while lower dosed animals show signs of disease around 37 weeks
(J:191425)
• a subset of tumors from mice treated with intratracheal delivery of cre-expressing adenovirus show loss of heterozygosity of Trp53
(J:191425)
• treatment of mice treated with intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus almost completely abrogates tumor formation
(J:191425)
• treatment of mice that have already formed lung tumors following intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus prevents further progression of tumors
(J:191425)
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus show evidence that high-grade adenocarcinomas acquire metastatic characteristics of non-small cell lung cancer
|
|
• tumors of mice treated with intratracheal delivery of cre-expressing adenovirus are adenocarcinomas and some evidence that high-grade adenocarcinomas acquire metastatic characteristics
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit large lungs filled with tumors and inflammation
• the inflammation that develops in the lungs of mice treated with intratracheal delivery of cre-expressing adenovirus occurs after initial nodules develop
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus develop a hunched posture in the most severe cases
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit a decline in weight
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit large lungs filled with tumors and inflammation
• the inflammation that develops in the lungs of mice treated with intratracheal delivery of cre-expressing adenovirus occurs after initial nodules develop
|
|
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes
(J:103407)
• following cre-adenovirus treatment, tumors occupy 27% of lung space
(J:103407)
• mice treated with intratracheal delivery of cre-expressing adenovirus develop lung cancer
(J:191425)
• mice infected with higher doses of cre expressing adenovirus present with clinical signs of lung cancer by 15 weeks of treatment while lower dosed animals show signs of disease around 37 weeks
(J:191425)
• a subset of tumors from mice treated with intratracheal delivery of cre-expressing adenovirus show loss of heterozygosity of Trp53
(J:191425)
• treatment of mice treated with intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus almost completely abrogates tumor formation
(J:191425)
• treatment of mice that have already formed lung tumors following intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus prevents further progression of tumors
(J:191425)
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus show evidence that high-grade adenocarcinomas acquire metastatic characteristics of non-small cell lung cancer
|
|
• tumors of mice treated with intratracheal delivery of cre-expressing adenovirus are adenocarcinomas and some evidence that high-grade adenocarcinomas acquire metastatic characteristics
|
|
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit labored breathing
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:191425 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop pancreatic ductal adenocarcinoma (PDAC)
|
|
• mice develop pancreatic ductal adenocarcinoma (PDAC)
|
|
• GFP+ PDAC cells form tumors form more metastases than GFP- PDAC cells when transplanted into recipient mice
• the highly metastatic PDAC subpopulation is enriched for hypoxia-induced genes
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| pancreatic ductal adenocarcinoma | DOID:3498 | J:245611 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• invasiveness of cancers considerably increased
• 56% of mice at 10-20 months
|
|
• 25% of cancerous mice have metastases
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• extended survival compared to control mice with normal Brf1
|
|
• at a reduced rate and with extended survival compared to control mice with normal Brf1
• however, tumors that do form lack recombined Brf1
|
|
• at a reduced rate and with extended survival compared to control mice with normal Brf1
• however, tumors that do form lack recombined Brf1
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all but one mouse, develop large, firm, fibrotic head of the pancreas tumors
• metastatic foci spread to the surface of the liver, lungs, diaphragm, and adrenals with occasional metastasis to the peripancreatic, mesenteric, and retroperitoneal lymph nodes
• mice exhibit the full spectrum of preinvasive lesions
• some tumors are minor, poorly differentiated, or undifferentiated with anaplastic or sarcomatoid features
|
|
• in young mice
|
|
• in 2 mice
|
|
• in one mouse
|
|
• some mice exhibit esophageal papillomas and hyperplasias or papillomatosis of the biliary tree unlike control mice
|
|
• in some mice
|
|
• hemorrhagic
|
|
• in tumor cells
|
|
• in some mice
|
|
• mice frequently exhibit small bowel obstructions unlike control mice
|
|
• mice exhibit the full spectrum of preinvasive lesions
• all but one mouse, develop large, firm, fibrotic head of the pancreas tumors
• metastatic foci spread to the surface of the liver, lungs, diaphragm, and adrenals with occasional metastasis to the peripancreatic, mesenteric, and retroperitoneal lymph nodes
• some tumors are minor, poorly differentiated, or undifferentiated with anaplastic or sarcomatoid features
|
|
• in young mice
|
|
• in 2 mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| pancreatic ductal adenocarcinoma | DOID:3498 | J:98936 | ||
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools